Valneva SE (FRA:AYJ)
2.740
-0.014 (-0.51%)
At close: Jul 18, 2025, 10:00 PM CET
Valneva SE Employees
Valneva SE had 713 employees as of December 31, 2024. The number of employees increased by 37 or 5.47% compared to the previous year.
Employees
713
Change (1Y)
37
Growth (1Y)
5.47%
Revenue / Employee
€260,950
Profits / Employee
€112,746
Market Cap
454.07M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
SAP SE | 109,121 |
Siemens Aktiengesellschaft | 327,000 |
Deutsche Telekom AG | 198,194 |
Allianz SE | 156,626 |
Rheinmetall AG | 28,539 |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
Siemens Energy AG | 98,000 |
Siemens Healthineers AG | 72,000 |
Valneva SE News
- 10 days ago - Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ in Elderly - Wallstreet:Online
- 10 days ago - Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly - GlobeNewsWire
- 10 days ago - Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults - Reuters
- 25 days ago - Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus - GlobeNewsWire
- 26 days ago - Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance - GlobeNewsWire
- 6 weeks ago - UK's MHRA suspends Valneva's chikungunya vaccine for elderly - Reuters
- 6 weeks ago - Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026 - Benzinga
- 6 weeks ago - Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ - Wallstreet:Online